Matinas BioPharma Holdings (MTNB) Assets Average (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Assets Average of $6.5 million for Q1 2026, down 46.98% year-over-year from $12.3 million in Q1 2025, and down 22.61% quarter-over-quarter from $8.5 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Assets Average (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Assets Average for 13 consecutive years, with $6.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 46.98% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $6.5 million (down 46.98% YoY), while the FY2025 annual figure was $9.9 million, down 47.41% from the prior year.
- Assets Average slipped to $6.5 million in Q1 2026 per MTNB's latest filing, from $8.5 million in the prior quarter.
- Across five years, Assets Average topped out at $58.6 million in Q1 2022 and bottomed at $6.5 million in Q1 2026.
- Historically, Assets Average has averaged $28.2 million across 5 years, with a median of $22.5 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average declined 18.29% — and 2025, when it plunged 53.01%.
- Matinas BioPharma Holdings' Assets Average stood at $46.2 million in 2022, then tumbled by 40.57% to $27.4 million in 2023, then tumbled by 39.49% to $16.6 million in 2024, then plunged by 49.11% to $8.5 million in 2025, then retreated by 22.61% to $6.5 million in 2026.
- Business Quant data shows MTNB's Assets Average at $6.5 million in Q1 2026, $8.5 million in Q4 2025, and $10.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.64 Mn |
| Mar 31, 2026 | 6.54 Mn |
| Dec 31, 2025 | 8.45 Mn |
| Sep 30, 2025 | 10.56 Mn |
| Jun 30, 2025 | 11.73 Mn |
| Mar 31, 2025 | 12.34 Mn |
| Dec 31, 2024 | 16.61 Mn |
| Sep 30, 2024 | 22.47 Mn |
| Jun 30, 2024 | 21.99 Mn |
| Mar 31, 2024 | 22.36 Mn |
| Dec 31, 2023 | 27.45 Mn |
| Sep 30, 2023 | 31.91 Mn |
| Jun 30, 2023 | 36.14 Mn |
| Mar 31, 2023 | 41.54 Mn |
| Dec 31, 2022 | 46.18 Mn |
| Sep 30, 2022 | 49.98 Mn |
| Jun 30, 2022 | 54.10 Mn |
| Mar 31, 2022 | 58.56 Mn |
| Dec 31, 2021 | 64.16 Mn |
| Sep 30, 2021 | 68.48 Mn |